FOB Synthesis

FOB Synthesis is a biotechnology company and contract research organization (CRO) based in Kennesaw, Georgia, specializing in the design and synthesis of complex small molecules. Founded in 2004, the company provides a range of services including medicinal chemistry, custom synthesis, and process development to the pharmaceutical and biotechnology industries. Beyond its service offerings, FOB Synthesis maintains an internal drug discovery pipeline focused primarily on infectious diseases, specifically targeting multi-drug resistant (MDR) Gram-negative bacteria. Their lead therapeutic candidate, FOB2077, is a next-generation carbapenem antibiotic designed to overcome prevalent resistance mechanisms. The company leverages its deep expertise in synthetic organic chemistry to support both its proprietary research and its collaborative partnerships.